🔧 They are installing a third FlexFactory platform while maintaining their mAb business.
🚀 Bionova aims to leverage Cytiva’s Fast Trak services for genomic medicine advancements.
💡 The FlexFactory offers flexibility, speed, and compliance, enhancing production efficiency.
🎉 Their facility in Texas recently celebrated its grand opening, with the new platform arriving in Q3 2025.
Introduction:
Bionova Scientific is significantly expanding its manufacturing capabilities by entering the advanced therapies market. This strategic move involves the installation of a third FlexFactory platform, aiming to bolster its production of genomic medicines while continuing its focus on monoclonal antibodies (mAb).
- Bionova Scientific is enhancing its manufacturing capabilities by integrating a third FlexFactory platform to support the production of advanced therapies.
- The company will utilize Cytiva’s Fast Trak process development services to facilitate its entry into genomic medicines.
- Fabio Fonseca, PhD, emphasizes that the collaboration with Cytiva will ensure high-quality production of plasmid DNA focused on patient safety.
- The FlexFactory platform boasts features that enhance operational speed, flexibility, and regulatory compliance.
- Bionova’s facility in The Woodlands, TX, recently celebrated its grand opening, with new manufacturing capabilities scheduled for delivery by Q3 2025.
Conclusion:
Bionova Scientific’s expansion into advanced therapies, facilitated by the FlexFactory platform, underscores its commitment to innovating within the biotech industry. This move is anticipated to enhance production efficiency and regulatory compliance, ultimately improving the availability of genomic medicines, with strategic implications for future growth and market resilience.
